凭借创新设计与技术实力，FattaLab®此前已斩获美国消费技术协会2026年国际消费电子展(CES)创新 奖，获得国际消费科技领域权威认可。 转自：扬子晚报 据了解，当前，代谢相关脂肪性肝病（MAFLD）已成为全球健康领域的重要挑战，其管理需求与日俱 增。传统检测方法主要依赖医院超声、CT或活检等手段，不仅流程相对繁琐，而且在可及性方面存在 明显不足，难以有效满足早期筛查与动态管理的实际需求。FattaLab®以家用化、无创化、定量化为核 心，实现"一次扫描、读懂肝健康"，与全球减重药物、体重管理、慢病干预趋势高度协同，为健康市场 提供精准检测入口，被视为打开脂肪肝管理赛道的"金铲子"。 扬子晚报网 2月18日讯（记者 姜婧仪 通讯员 江轩）近日，意领科技有限公司正式宣布，旗下FattaLab® 肝脏脂肪测量仪获得美国食品药品监督管理局（FDA）510(k)注册批准。作为全球首款轻量化肝脏脂肪 定量检测设备，此次获批标志着中国原创肝脏健康监测技术正式迈入国际消费医疗赛道，推动肝脏健康 管理进入精准、便捷、可及的3.0时代。依托南京江宁的全球超级工厂与产业化基地，FattaLab®将快速 实现规模化交付，服务 ...

Bausch + Lomb (NYSE:BLCO) Q4 2025 Earnings call February 18, 2026 08:00 AM ET Company ParticipantsAndrew Stewart - President of Global Pharmaceuticals and International ConsumerBrent Saunders - Chairman and CEODavid Roman - Managing DirectorDouglas Miehm - Managing DirectorGeorge Gadkowski - VP of Investor Relations and Business InsightsJoanne Wuensch - Managing Director, Head of U.S. Healthcare ResearchPatrick Wood - Managing DirectorSam Eldessouky - CFOYehia Hashad - EVP and Chief Medical OfficerConferenc ...

Core Viewpoint - The company expresses gratitude to clients and partners while reflecting on the challenges and opportunities of the past year, emphasizing its commitment to innovation and customer value in the face of digital transformation [4]. Group 1: Company Vision and Strategy - The company aims to embrace change with an open attitude, refine its products through solid internal capabilities, and connect the future with innovative thinking [4]. - The focus will remain on enhancing technical capabilities and deepening partnerships to navigate uncertainties and achieve high-quality development [4]. Group 2: Industry Context - The digital and intelligent transformation is reshaping various industries, presenting unprecedented opportunities for growth and innovation [4]. - The company acknowledges the importance of teamwork and client trust in achieving technological breakthroughs [4]. Group 3: Product Development - The company has recently launched two electronic endoscope products, indicating a commitment to advancing medical technology [6]. - The industry is witnessing significant investment in innovative endoscope technology, as evidenced by a recent financing round for a domestic company [5].

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAngie Wirick - CFODanny Stauder - Director of Equity Research in Medical TechnologyJohn McAulay - Associate VPMarissa Bych - Managing DirectorMike Carrel - President and CEOConference Call ParticipantsLily Lozada - Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMike Matson - Senior AnalystSuraj Kalia - Managing Director and Senior Analyst in Medical Tec ...

Financial Data and Key Metrics Changes - The company reported net sales of $100.3 million for the full year 2025, representing a 54% year-over-year growth [11] - Gross margin for the full year was 55.4%, slightly expanding year-over-year [11] - In Q4, net sales reached $32.1 million, reflecting a 57% growth year-over-year [12] - Q4 gross margin was 59%, an increase of 179 basis points year-over-year [14] Business Line Data and Key Metrics Changes - The company added approximately 20,000 new users in 2025, more than doubling its installed base to over 35,000 users [8] - New patient starts through the pharmacy channel grew to the high 20s percentage for the full year 2025, compared to a high single-digit percentage in the prior year [11] - In Q4, 5,592 new patient starts were recorded, a 37% increase year-over-year [12] Market Data and Key Metrics Changes - Approximately 69% of new patient starts in Q4 came from individuals previously using multiple daily injections, indicating market expansion [17] - The company established formulary agreements with all major pharmacy benefit managers in the U.S. [9] Company Strategy and Development Direction - The company aims to revolutionize diabetes care by improving outcomes and reducing the burden for users [7] - The focus is on expanding the pharmacy channel strategy and enhancing the product pipeline, including the development of the Mint patch pump and the bihormonal system [10][39] - The company plans to add at least 20 new sales territories in 2026 to enhance market coverage [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2026 revenue guidance of $130 million to $135 million, despite potential headwinds from pharmacy channel dynamics [19] - The company anticipates a decline in Q1 2026 revenue compared to Q4 2025 due to seasonal factors [22][70] - Management remains optimistic about the long-term potential of the bihormonal system and its ability to transform diabetes management [42] Other Important Information - The company received a Warning Letter from the FDA regarding quality system observations, which management is actively addressing [30][38] - As of December 31, 2025, the company had approximately $265 million in cash and investments, indicating strong capitalization for future initiatives [18] Q&A Session Summary Question: Can you discuss the level of conservatism in the 2026 guidance? - Management refrained from labeling the guidance as conservative but expressed confidence in meeting the communicated targets [47] Question: What is the outlook for gross margin in 2026? - The guidance for gross margin was slightly lower than expected due to potential short-term headwinds from pharmacy conversions [49][51] Question: How did the pump market perform in Q4? - Management did not have specific insights on market share due to competitors not yet reporting their earnings [55] Question: Can you elaborate on the sales territory expansion? - The company plans significant expansion in the first half of 2026, with at least 20 new territories being added [60] Question: What are the concerns regarding hypoglycemia? - Management indicated that rates of hypoglycemia are consistent with clinical trials and are significantly lower than ADA guidelines [86]

Financial Data and Key Metrics Changes - Glaukos reported record fourth quarter consolidated net sales of $143.1 million, up 36% on a reported basis and 34% on a constant currency basis compared to the year-ago quarter [7] - For the full year of 2025, consolidated record net sales reached $507.4 million, growing 32% versus 2024 [7] - The company reaffirmed its full year 2026 net sales guidance range of $600 million to $620 million, implying over 20% year-over-year growth at the midpoint [7] Business Line Data and Key Metrics Changes - The U.S. glaucoma franchise achieved record fourth quarter net sales of $86.4 million, reflecting a strong year-over-year growth of 53%, driven by iDose TR, which generated approximately $45 million in sales during the fourth quarter [9] - The international glaucoma franchise delivered net sales of $32.8 million, with year-over-year growth of 18% on a reported basis and 13% on a constant currency basis [11] - The corneal health franchise reported net sales of $24 million, with year-over-year growth of 12%, including $21.4 million from Photrexa [12] Market Data and Key Metrics Changes - The company noted strong physician adoption of iDose TR, with sales of approximately $136 million in 2025, indicating positive clinical outcomes and growing contributions [9] - The international market is expected to face competitive product trialing headwinds in major markets, partially offset by contributions from iStent infinite following its EU MDR certification [11] Company Strategy and Development Direction - Glaukos aims to advance the interventional glaucoma treatment paradigm with iDose TR and launch Epioxa, targeting new markets in interventional keratoconus and rare diseases [8] - The company is focused on capital allocation, emphasizing ROI-driven investments and cash flow while advancing a robust industry-leading pipeline [9] - The FDA approval of Epioxa is seen as a pivotal moment, allowing the company to redefine its go-to-market approach and expand patient care access [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining strong growth momentum into 2026, driven by the advancements in iDose TR and the launch of Epioxa [8] - The company acknowledged potential challenges in the transition from Photrexa to Epioxa, particularly in Q2 and Q3, but expects stronger results in Q4 as the J-code becomes effective [37] - Management highlighted the importance of clinical education and payer engagement to ensure successful adoption of Epioxa [25] Other Important Information - Glaukos has invested over $1 billion in R&D since inception, focusing on chronic and rare ophthalmic diseases [21] - The company is committed to pioneering new marketplaces within ophthalmology, emphasizing innovation as a core value [22] Q&A Session Summary Question: Can you elaborate on the early positive coverage determinations for Epioxa? - Management noted that early positive outcomes have been observed with a handful of Medicaid societies and one of the larger Blue plans, with no formal pushback on pricing dynamics [25] Question: What drove the sequential deceleration in iDose revenue in Q4? - Management indicated that the mix shift towards Medicare Advantage and specific dynamics related to glaucoma procedures impacted revenue, but they expect continued growth in Q1 [29] Question: Can you provide more detail on the components of the FY 2026 guidance? - Management expects high single-digit growth internationally, with U.S. glaucoma growth driven entirely by iDose TR, while corneal health is expected to grow modestly with some volatility [35][37] Question: How do you view the interplay between iDose and TREX? - Management emphasized the goal of providing multiple treatment options for patients, with expectations for different surgeons to choose between iDose TR and TREX based on clinical profiles [49] Question: What are the expectations for operating expenses in 2026? - Management anticipates mid-teen year-over-year growth in operating expenses, aiming for around $555 million to $560 million, while maintaining operating leverage [54]

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Company ParticipantsAngie Wirick - CFODanny Stauder - Director of Equity Research in Medical TechnologyJohn McAulay - Associate VPMarissa Bych - Managing DirectorMike Carrel - President and CEOConference Call ParticipantsLily Lozada - Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMike Matson - Senior AnalystSuraj Kalia - Managing Director and Senior Analyst in Medical Tec ...

Financial Data and Key Metrics Changes - The company reported net sales of $100.3 million for the full year 2025, representing a 54% year-over-year growth [11] - Gross margin for the full year was 55.4%, slightly expanding year-over-year [11] - In Q4, net sales reached $32.1 million, reflecting a 57% growth year-over-year [12] - Q4 gross margin was 59%, an increase of 179 basis points year-over-year [14] Business Line Data and Key Metrics Changes - The company added approximately 20,000 new users in 2025, more than doubling the installed base to over 35,000 users [8] - New patient starts through the pharmacy channel grew to the high 20s percentage for the full year 2025, compared to a high single-digit percentage in the prior year [11] - In Q4, 5,592 new patient starts were recorded, a 37% increase year-over-year [12] Market Data and Key Metrics Changes - Approximately 69% of new patient starts in Q4 came from individuals previously using multiple daily injections, indicating market expansion [17] - The company established formulary agreements with all major pharmacy benefit managers in the U.S. [9] Company Strategy and Development Direction - The company aims to revolutionize diabetes care by improving outcomes and reducing the burden for users [7] - The focus is on expanding the pharmacy channel strategy and enhancing the product pipeline, including the development of the Mint patch pump and the Bihormonal System [10][39] - The company plans to add at least 20 new sales territories in 2026 to enhance market coverage [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to resolve FDA concerns and improve quality systems following a warning letter [30][38] - The company anticipates continued growth in the pharmacy channel, which is expected to drive revenue and gross margin improvements [20][28] - Management highlighted the importance of maintaining cost discipline while expanding operations [19] Other Important Information - The company has approximately $265 million in cash and investments, indicating strong capitalization to fund key initiatives [18] - The guidance for 2026 includes expected revenue of $130 million to $135 million and gross margin between 55.5% and 57.5% [19] Q&A Session Summary Question: Can you discuss the level of conservatism in the 2026 guidance? - Management indicated confidence in hitting the guidance but acknowledged that outperforming in the pharmacy channel could create short-term revenue headwinds [48] Question: What is the outlook for gross margin in 2026? - Management explained that the gross margin guidance reflects potential short-term impacts from increased pharmacy conversions [49][50] Question: How did the pump market perform in Q4? - Management stated they do not have insights on market share performance yet as competitors have not reported their earnings [54] Question: Can you elaborate on the sales territory expansion? - Management confirmed that a significant portion of the territory expansion will occur in the first half of 2026 [58] Question: Why is the company expanding by only 20 territories? - Management emphasized a deliberate approach to expansion, balancing growth with operational capabilities and future product launches [81]

Financial Data and Key Metrics Changes - For the full year 2025, Beta Bionics reported net sales of $100.3 million, representing a 54% year-over-year growth. The gross margin was 55.4%, which expanded slightly year-over-year [10][11] - In Q4 2025, the company generated $32.1 million in net sales, reflecting a 57% growth year-over-year, with a gross margin of 59%, an increase of 179 basis points year-over-year [11][12] Business Line Data and Key Metrics Changes - The company added approximately 20,000 new users in 2025, more than doubling its installed base to over 35,000 users [6][10] - In Q4, 5,592 new patient starts were recorded, a 37% increase year-over-year, with a growing percentage of new patient starts reimbursed through the pharmacy channel [11][12] Market Data and Key Metrics Changes - The percentage of new patient starts through the pharmacy channel grew to the high 20s% for the full year 2025, compared to a high single-digit percentage in the previous year [10][12] - In Q4, approximately 69% of new patient starts came from individuals who previously used multiple daily injections, indicating an expansion of the market for insulin pumps [16] Company Strategy and Development Direction - Beta Bionics aims to revolutionize diabetes care by improving access and outcomes for people with diabetes through innovative products like the iLet and the upcoming Mint patch pump [5][9] - The company has established formulary agreements with major pharmacy benefit managers, enhancing user access to the iLet and its consumables at lower out-of-pocket costs [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue expanding the pump market and capturing market share, with revenue guidance for 2026 set at $130 million to $135 million [18][19] - The company acknowledged challenges related to seasonality in the insulin pump market, particularly the expected decline in Q1 2026 revenue compared to Q4 2025 [21][23] Other Important Information - The company received a Warning Letter from the FDA regarding quality system observations, which management is actively addressing through remediation efforts [29][30] - Beta Bionics is progressing with its R&D initiatives, including the development of the Mint patch pump and the bihormonal system, with significant milestones achieved in clinical trials [40][41] Q&A Session Summary Question: Can you discuss the level of conservatism in the 2026 guidance? - Management refrained from labeling the guidance as conservative but expressed confidence in meeting the communicated revenue targets, considering potential headwinds from pharmacy channel performance [46][47] Question: What is the outlook for the U.S. pump market in Q4? - Management did not provide specific insights on market share due to competitors not yet reporting their earnings [53][55] Question: How will the expansion of sales territories impact market coverage? - The company plans to add at least 20 new sales territories in 2026, with a significant portion of this expansion occurring in the first half of the year [56][60] Question: What are the expectations for Q1 2026 revenue? - Management indicated that Q1 2026 is expected to see a larger decline in revenue compared to the previous year, influenced by unique product launches in Q4 2024 [63][68] Question: How does the company address concerns regarding hypoglycemia? - Management stated that the rates of hypoglycemia with the iLet are consistent with clinical trials and significantly lower than ADA guidelines, emphasizing the safety of their product [85][86]

AtriCure (NasdaqGM:ATRC) Q4 2025 Earnings call February 17, 2026 04:30 PM ET Speaker10Good afternoon, and welcome to AtriCure's fourth quarter and full year 2025 earnings conference call. This call is being recorded for replay purposes, and at this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session following prepared remarks from AtriCure's management. I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory com ...